MUC16 and hepatocellular carcinoma: Additionally, the recurrence-free survival rates for HCC patients in the H-CA125 group at 1, 3, and 5 years were 37.1%, 26.3%, and 17.4%, respectively, and 64.5%, 44.5%, and 31.7%, respectively, for HCC patients in the N-CA125 group (p <0.0001, Figure 2B).